[1] [1] GU B X, SHANG X G, YAN M Q, et al. Variations in incidence and mortality rates of endometrial cancer at the global, regional, and national levels, 1990–2019[J]. Gynecol Oncol, 2021, 161(2): 573-580.

[2] [2] ZHENG R S, CHEN R, HAN B F, et al. Cancer incidence and mortality in China, 2022[J]. Chin J Oncol, 2024, 46(3): 221-231.

[3] [3] GUTIERREZ C, SCHIFF R. HER2: biology, detection, and clinical implications[J]. Arch Pathol Lab Med, 2011, 135(1): 55-62.

[4] [4] PATEL A, UNNI N, PENG Y. The changing paradigm for the treatment of HER2-positive breast cancer[J]. Cancers (Basel), 2020, 12(8): 2081.

[5] [5] YOON J, OH D Y. HER2-targeted therapies beyond breast cancer—an update[J]. Nat Rev Clin Oncol, 2024, 21: 675-700.

[6] [6] NETWORK C G A R, KANDOTH C, SCHULTZ N, et al. Integrated genomic characterization of endometrial carcinoma[J]. Nature, 2013, 497(7447): 67-73.

[7] [7] KLC T R, WU S, WILHITE A M, et al. HER2 in uterine serous carcinoma: testing platforms and implications for targeted therapy[J]. Gynecol Oncol, 2022, 167(2): 289-294.

[8] [8] FLEMING G F, SILL M W, DARCY K M, et al. Phase Ⅱ trial of trastuzumab in women with advanced or recurrent, HER2-positive endometrial carcinoma: a Gynecologic Oncology Group study[J]. Gynecol Oncol, 2010, 116(1): 15-20.

[9] [9] BRUCE S F, WU S, RIBEIRO J R, et al. HER2+ endometrioid endometrial cancer possesses distinct molecular and immunologic features associated with a more active immune microenvironment and worse prognosis[J]. Gynecol Oncol, 2023, 172: 98-105.

[10] [10] YOSHIDA H, NISHIKAWA T, MATSUMOTO K, et al. Histopathological features of HER2 overexpression in uterine carcinosarcoma: proposal for requirements in HER2 testing for targeted therapy[J]. Virchows Arch, 2021, 478(6): 1161-1171.

[11] [11] FADER A N, ROQUE D M, SIEGEL E, et al. Randomized phase Ⅱ trial of carboplatin-paclitaxel compared with carboplatin-paclitaxel-trastuzumab in advanced (stage Ⅲ-Ⅳ) or recurrent uterine serous carcinomas that overexpress Her2/neu (NCT01367002): updated overall survival analysis[J]. Clin Cancer Res, 2020, 26(15): 3928-3935.

[12] [12] GOGIA P, ASHRAF H, BHASIN S, et al. Antibody-drug conjugates: a review of approved drugs and their clinical level of evidence[J]. Cancers (Basel), 2023, 15(15): 3886.

[13] [13] MERIC-BERNSTAM F, MAKKER V, OAKNIN A, et al. Efficacy and safety of trastuzumab deruxtecan in patients with HER2-expressing solid tumors: primary results from the DESTINY-PanTumor02 phase Ⅱ trial[J]. J Clin Oncol, 2024, 42(1): 47-58.

[14] [14] MAHESHWARI E, NOUGARET S, STEIN E B, et al. Update on MRI in evaluation and treatment of endometrial cancer[J]. Radiographics, 2022, 42(7): 2112-2130.

[15] [15] BEREK J S, MATIAS-GUIU X, CREUTZBERG C, et al. FIGO staging of endometrial cancer: 2023[J]. Int J Gynaecol Obstet, 2023, 162(2): 383-394.

[17] [17] MILESHKIN L, EDMONDSON R, O'CONNELL R L, et al. Phase 2 study of anastrozole in recurrent estrogen (ER)/progesterone (PR) positive endometrial cancer: The PARAGON trial - ANZGOG 0903[J]. Gynecol Oncol, 2019, 154(1): 29-37.

[18] [18] WHO Classification of Tumours Editorial Board. Female genital tumours[M]//WHO classification of tumours·5th edition. Lyon: IARC Press, 2020.

[19] [19] JIANG X Y, JIA H D, ZHANG Z Y, et al. The feasibility of combining ADC value with texture analysis of T2WI, DWI and CE-T1WI to preoperatively predict the expression levels of ki-67 and p53 of endometrial carcinoma[J]. Front Oncol, 2022, 11: 805545.

[20] [20] ZHANG Q, YU X D, LIN M, et al. Multi-b-value diffusion weighted imaging for preoperative evaluation of risk stratification in early-stage endometrial cancer[J]. Eur J Radiol, 2019, 119: 108637.

[21] [21] ABADA E, KIM S, JANG H, et al. Human epidermal growth factor receptor-2 (HER2) expression in FIGO3 high-grade endometrial endometrioid carcinoma: Clinicopathologic characteristics and future directions[J]. Gynecol Oncol, 2024, 185: 25-32.

[22] [22] VERMIJ L, HOREWEG N, LEON-CASTILLO A, et al. HER2 status in high-risk endometrial cancers (PORTEC-3): relationship with histotype, molecular classification, and clinical outcomes[J]. Cancers (Basel), 2020, 13(1): 44.

[23] [23] DIVER E J, FOSTER R, RUEDA B R, et al. The therapeutic challenge of targeting HER2 in endometrial cancer[J]. Oncologist, 2015, 20(9): 1058-1068.

[24] [24] LESLIE K K, SILL M W, LANKES H A, et al. Lapatinib and potential prognostic value of EGFR mutations in a Gynecologic Oncology Group phase Ⅱ trial of persistent or recurrent endometrial cancer[J]. Gynecol Oncol, 2012, 127(2): 345-350.

[25] [25] AHN E R, ROTHE M, MANGAT P K, et al. Pertuzumab plus trastuzumab in patients with endometrial cancer with ERBB2/3 amplification, overexpression, or mutation: results from the TAPUR study[J]. JCO Precis Oncol, 2023, 7: e2200609.

[26] [26] NISHIKAWA T, HASEGAWA K, MATSUMOTO K, et al. Trastuzumab deruxtecan for human epidermal growth factor receptor 2-expressing advanced or recurrent uterine carcinosarcoma (NCCH1615): the STATICE trial[J]. J Clin Oncol, 2023, 41(15): 2789-2799.

[27] [27] MCNAMARA B, GREENMAN M, PEBLEY N, et al. Antibody-drug conjugates (ADC) in HER2/neu-positive gynecologic tumors[J]. Molecules, 2023, 28(21): 7389.

[28] [28] XU M L, KONG Y H, XING P F, et al. An open-label, multicenter, phase Ⅱ study of RC48-ADC combined with radiotherapy, PD-1/PD-L1 inhibitor sequential GM-CSF and IL-2 for salvage therapy in patients with HER2-expressing advanced solid tumors (PRaG3.0)[J]. J Clin Oncol, 2022, 40(16_suppl): e14565.

[29] [29] REYES-PREZ J A, VILLASEOR-NAVARRO Y, JIMNEZ DE LOS SANTOS M E, et al. The apparent diffusion coefficient (ADC) on 3-T MRI differentiates myometrial invasion depth and histological grade in patients with endometrial cancer[J]. Acta Radiol, 2020, 61(9): 1277-1286.

[30] [30] CELLI V, GUERRERI M, PERNAZZA A, et al. MRI-and histologic-molecular-based radio-genomics nomogram for preoperative assessment of risk classes in endometrial cancer[J]. Cancers (Basel), 2022, 14(23): 5881.

[31] [31] MA X L, REN X J, MA F H, et al. Volumetric apparent diffusion coefficient (ADC) histogram metrics as imaging biomarkers for pretreatment predicting response to fertility-sparing treatment in patients with endometrial cancer[J]. Gynecol Oncol, 2022, 165(3): 594-602.